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The Influence of the 1997 Updated Classification
Criteria for Systemic Lupus Erythematosus:
Epidemiology, Disease Presentation, and Patient
Management
GRO ØSTLI EILERTSEN, ANDREA BECKER-MEROK, and JOHANNES C. NOSSENT
ABSTRACT. Objective. The 1997 update of the American College of Rheumatology classification criteria
(ACR97) for systemic lupus erythematosus (SLE) has not been validated. We determined to what
extent their introduction influenced the epidemiology and clinical characteristics of the disease in
northern Norway.
Methods. Annual incidence and point-prevalence rates, clinical manifestations, and outcome were
determined in an inception cohort of patients with SLE in northern Norway, included between 1996
and 2006, using ACR97 criteria (97acr). These findings were compared with a cohort from the same
area enrolled 1978-1995 using the 1982 revised criteria ACR82 (82acr).
Results. The mean annual incidence of SLE was 3.00 for cohort 97acr (n = 58) versus 2.63 for cohort
82acr (n = 81) (p = 0.5). All patients in the 97acr cohort also fulfilled the 1982 criteria; however, sig-
nificantly fewer patients presented with discoid rash [odds ratio (OR) 0.31)], arthritis (OR 0.24),
renal (OR 0.28) or hematological disorder (OR 0.27), and significantly more with anti-dsDNA (OR
2.57) and antiphospholipid antibodies (OR 27.9). Initial treatment with intravenous pulse methyl-
prednisolone (OR 9.23), azathioprine (OR 6.32), and low-dose aspirin (OR 20.9) was increased in
cohort 97acr. Five- (95.2%) and 10-year survival (91.9%) rates were also improved for cohort 97acr.
Conclusion. The ACR97 criteria set has construct validity compared to the ACR82 criteria set. SLE
incidence remains unchanged in northern Norway, but a significant reduction of renal disease and
further improvements in survival rates occurred simultaneously with increased serological surveil-
lance with ELISA-based assays and early immunosuppressive and anticoagulant therapy.
(J Rheumatol First Release Jan 15 2009; doi:10.3899/jrheum.080574)
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Systemic lupus erythematosus (SLE) is one of the most
common systemic autoimmune diseases, characterized by a
highly variable clinical presentation and an unpredictable
disease course1,2. There are considerable regional differ-
ences in the epidemiology of SLE, with the lowest incidence
rates observed in Caucasian populations3-6. There has been
a trend towards an increased incidence and prevalence of
SLE for Caucasian cohorts in the USA7-9, while the inci-
dence has been stable in southern Sweden10.
The 1982 revised criteria for the classification of SLE by
the American College of Rheumatology (ACR) were modi-
fied in 199711,12, where the presence of LE cells was
replaced with the presence of antiphospholipid antibodies
(aPL). These recommendations reflected that few laborato-
ries were still performing the LE cell assay. The recommen-
dations for the 1997 update were consensus-based and the
operating characteristics of the updated criteria set have
never been validated. As persistent aPL can also be found in
many other conditions13-16, the inclusion of aPL in ACR97
could, in theory, change SLE incidence and prevalence, e.g.,
by including patients with undifferentiated connective tissue
disease or antiphospholipid syndrome (APS). In the same
way, the association between aPL and thrombosis16,17 may
affect the spectrum of disease manifestations by emphasiz-
ing vascular events in SLE. While the prognosis for patients
with SLE has improved over time and standardized mortali-
ty rates (SMR) have decreased in Caucasian SLE cohorts,
mortality in patients with SLE remains higher than in
matched controls with cardiovascular events as a major
cause of death7,18,19. Our study compared the epidemiologi-
cal and clinical characteristics of a recent SLE inception
cohort defined by the 1997 update of the classification crite-
ria of SLE (ACR97) with an existing cohort from the same
region classified according to the 1982 revised ACR criteria
(ACR82), where one criterion is presence of LE cells as
opposed to ACR97.
MATERIALS AND METHODS
The catchments area for our study consisted of the 2 northernmost counties
of Norway (population in 1993 was 224,724 inhabitants, population on
January 1, 2007, 226,898) representing 5% of the Norwegian population
(Statistics Norway; www.ssb.no). The Department of Rheumatology at
University Hospital of Northern Norway is the only rheumatology center
in this area, which otherwise has 3 local hospitals and no privately prac-
ticing rheumatologists. Data sources were hospital patient registries (in-
and outpatients) for all departments in these 4 hospitals. Patients were
identified through computerized diagnostic registry searches for
International Classification of Diseases-10 codes for SLE (M32.0, M32.1,
M32.8, and M32.9), Sjögren’s syndrome (M35.0), unclassified connec-
tive tissue disease (M35.9), and discoid lupus (L93.0). All adult patients
(16 yrs or older) who fulfilled 4 or more of the ACR9712 criteria in the
11-year period prior to January 1, 2007, were included and designated
cohort 97acr. Children with SLE were registered separately and included
in prevalence data when reaching 16 years of age (during the study peri-
od). Cohort 82acr is a previously reported cohort of SLE incident cases
defined by ACR82 during 1978–9511, constituted in the same area and
manner with a high case ascertainment5. Demographic data, clinical data,
disease activity by SLE Disease Activity Index (SLEDAI) and Systemic
Lupus International Collaborating Clinics/ACR Damage Index
(SLICC/ACR DI) were collected by a single investigator and stored in a
central database as described5. Missing data were considered to indicate
negative findings. Scoring of both SLEDAI and SLICC/ACR DI have
been validated20,21.
Antinuclear antibody (ANA) screening was performed at a single clin-
ical immunology department by immunofluorescence techniques until
1994 and by automated ELISA since then. All ANA-positive sera were
routinely tested for the presence of antibodies (Ab) against double-strand-
ed DNA (anti-dsDNA) by Crithidia luciliae immunofluorescence assay
and ELISA (since 1995), as well as antibodies against Ro (anti-SSA), La
(anti-SSB), Smith (anti-Sm), and anti-U1 small nuclear ribonucleoparticle
(anti-U1-snRNP), all by ELISA techniques. Both IgG and IgM isotypes of
anticardiolipin (aCL) antibodies were tested by commercial ELISA kits
since 1992 (cutoff levels for positive findings > 16 IU), while lupus anti-
coagulant (LAC) was tested in a phospholipid-dependent coagulation
assay22.
Data reported are median values unless indicated otherwise.
Continuous data were analyzed by Mann-Whitney U-test, Poisson distribu-
tion contingency tables, or Fisher’s exact test in case of low numbers.
Annual incidence rate (AIR) and point-prevalence (PP) are reported per
100,000. Survival rates were estimated by Kaplan-Meier method and com-
pared by log-rank testing. Standardized mortality rates were calculated by
randomly assigning each patient 5 controls, born in the same year and
month and matched for sex and municipality identified by area code. The
prognostic values of potential survival predictors were analyzed by Cox
proportional hazards models. Hazard ratios (HR) are reported with 95%
confidence interval (95% CI). All statistical analyses were performed with
SPSS 11.0 and Epi-Info 4.1. The regional ethics board approved the study
protocol and all patients gave written informed consent for the identified
use of their data.
RESULTS
Incidence data. Inception cohort 97acr contained 58 patients
with new-onset SLE and was similar to cohort 82acr with
regard to age (39.4 vs 41.7 yrs; p = 0.6), sex (84.5% vs
85.2% female; p = 0.4), and ethnicity (1.7% vs 1.2% non-
Caucasian; p = 0.8). The estimated average AIR was 2.8
(95% CI 2.2–3.3) for the whole study period (1978–2006),
with no significant difference between the AIR for cohort
97acr (3.00, 95% CI 2.0–4.0) and cohort 82acr (2.63, 95%
CI 1.9–3.7) (p = 0.5; Table 1). The overall AIR was highest
among women 30–49 years of age in both cohorts (8.27 vs
5.79; p = 0.093; Table 1).
Prevalence data. As 16 patients migrated and 40 patients
died during the whole study period they were excluded from
prevalence analysis. Another 19 patients with SLE diag-
nosed before 1978 and 12 pediatric patients reaching 16
years of age during the observation period were included in
the prevalence data for a total number of 114 adult patients.
The crude point-prevalence at January 1, 2007, was 64.1
overall, 108.6 for women, and 20.0 for men per 100,000
(Figure 1). The disease prevalence increased gradually dur-
ing the observation period, with the highest point-prevalence
at 124.9 seen in women age 50 years or older (data not
shown).
Clinical and laboratory manifestations. The time between
onsets of the first SLE-related symptom and fulfilment of
ACR criteria was 1 year in both cohorts, regardless of age
and sex (data not shown). The mean number of classification
criteria in cohort 97acr was significantly lower than in
cohort 82acr [4.6 (range 4–7) vs 6.0 (range 4–9); p < 0.001].
In cohort 97acr, aPL antibodies occurred simultaneously
with anti-dsDNA or anti-Sm antibodies in 93.3% at diagno-
sis; in 6.7% aPL presence was the only immunological cri-
terion, but these patients fulfilled at least 4 other criteria at
diagnosis. Overall, all patients in the 97acr cohort fulfilled
at least 4 of the ACR82 criteria, even though the assay for
LE cells was not available for the patients in this cohort. In
cohort 82acr, 33% of the patients with SLE presented with
positive LE cells, but only 6.2% as the fourth and only
immunologic classification criterion. At diagnosis, SLEDAI
scores were similar for both cohorts [8.3 (95% CI 6.6–10.0)
vs 8.8 (95% CI 7.4–10.4); p = 0.445], but clinical features
differed considerably (Table 2). In cohort 97acr significant-
ly fewer presented with discoid rash (OR 0.31), arthritis (OR
0.24), proteinuria (OR 0.22), leukopenia (OR 0.35), or lym-
phopenia (OR 0.25). In contrast, the frequencies of anti-
dsDNA antibodies and aPL antibodies were significant
increased in cohort 97acr (OR 2.57 and 20.9, respectively),
while no significant increase was seen for other autoanti-
bodies such as anti-SSA (33% vs 20%), anti-SSB (10% vs
7%), rheumatoid factor (12% vs 17%), or anti-U1-snRNP
(12% vs 9%) (data not shown).
To explore this increase in serological classification cri-
teria further, we also compared the intensity of serological
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surveillance. With the exception of ANA-negative patients,
all patients in both cohorts were surveyed for anti-dsDNA
Ab (98% vs 99%; p = 0.9). The annual number of anti-
dsDNA assays performed was significantly higher in the
97acr cohort (2.32 vs 1.34; p < 0.001). As the assay for aCL
antibodies was introduced in 1992, the data of aPL profiles
at diagnosis were biased. When including all available data
on the ever-presence of aPL, there was a slight, although not
statistically significant, increase in the number of aPL-posi-
tive patients in the 97acr cohort (41 % vs 31%; p = 0.201),
possibly because more 97acr patients were ever tested for
aPL (97% vs 83 %; p = 0.014). The increase in the annual
numbers of aPL tests performed in cohort 97acr (2.3 vs 1.4;
p < 0.001) was similar to that for anti-dsDNA testing.
Disease course. Initial treatment: During the first 4 months
of disease there was increased use of azathioprine (p =
0.011), intravenous pulse methylprednisolone (p = 0.015),
and low-dose aspirin (p < 0.001) in cohort 97acr (Table 2).
The number of patients treated with nonsteroidal antiin-
flammatory drugs, hydroxychloroquine, cyclophosphamide,
methotrexate, cyclosporineA, plasmapheresis, oral corticos-
teroids, warfarin, or antihypertensive drugs showed no sig-
nificant differences (data not shown).
Mortality: At the end of the observation period, 5 women
in cohort 97acr had died, for a case fatality rate of 8.6%. At
death, disease duration was 19 months (range 3–77) and age
50 years (range 19–75). The overall adjusted SMR was
highest in cohort 97acr: overall 3.00 versus 1.88 and women
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Table 1. Mean annual incidence rates (AIR) for SLE per 100,000 at risk by age and sex, comparison between 2 cohorts in northern Norway. Patients in 97acr
cohort were classified by ACR97, while ACR82 was used in 82acr cohort.
97acr Cohort, 82acr Cohort, 97acr vs 82acr, Whole Period
Population 1996–2006 1978–1995 p 1978–2006
n AIR (95% CI) n AIR (955 CI) n AIR (95% CI)
Children 47,084 5 0.9 (0.0–1.9) 6 0.7 (0.0–1.4) 0.494 11 0.8 (0.3–1.3)
Adults 177,640 58 3.0 (2.0–4.0) 81 2.6 (1.9–3.7) 0.500 139 2.8 (2.2–3.3)
Men 89,952 9 0.9 (0.0–1.8) 12 0.8 (0.4–1.1) 0.738 21 0.8 (0.4–1.2)
Women 87,688 49 5.1 (3.7–6.4) 69 4.6 (3.1–6.1) 0.208 118 4.8 (3.7–5.8)
Female age groups, yrs
16–29 25,178 12 4.3 (1.8–6.9) 20 4.4 (1.6–7.2) 0.701 32 4.4 (2.5–6.3)
30–49 30,798 28 8.3 (5.4–1.1) 31 5.8 (3.2–8.4) 0.093 59 6.7 (4.9–8.6)
Over 50 31,712 9 2.6 (0.7–4.4) 18 3.2 (1.3–5.0) 0.848 27 2.9 (1.7–4.2)
Total number in population in 1993 was 224,724 inhabitants. Children: < 16 yrs; ACR: American College of Rheumatology; ACR97: 1997 update of criteria
for systemic lupus erythematosus (SLE); ACR82: 1982 revised criteria. n : number of incident cases during the period.
Figure 1. Prevalence rates of SLE in Northern Norway, 1978–2006.
3.75 versus 1.94 (Table 3). In cohort 82acr, 25 patients had
died (case fatality rate 30.9%) after longer disease duration
(98 months, range 1–209) and at higher age (66 yrs, range
19–81) than in cohort 97acr.
Survival: Ten-year survival for patients with SLE was
significantly lower than in the general population (p = 0.004
for cohort 97acr, and p < 0.001 for cohort 82acr). Five- and
10-year survival estimates were higher in cohort 97acr
(95.2% and 91.9%, respectively) than in cohort 82acr
(90.8% and 80.5%), but this increase was not statistically
significant (Figure 2).
Cox proportional hazard models identified potential pre-
dictors of survival within 10 years of diagnosis (p < 0.1
to enter, p < 0.05 to stay). In cohort 97acr, the initial
presence of renal disease (HR 10.9; p = 0.009), initial
treatment with pulse methylprednisolone (HR 1.5; p =
0.012), low-dose aspirin (HR 1.3; p = 0.005), and anti-
hypertensive drugs (HR 1.3; p = 0.001) were associated
with poorer survival by univariate analysis. The low
number of events did not allow multivariate analysis of
the interdependency of these predictors. In cohort
82acr, age > 50 years at diagnosis was the sole
independent predictor for poorer survival (HR 12.2;
p ≤ 0.001; Table 4).
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Table 2. SLE manifestations at diagnosis. Treatment during the first 4 months after diagnosis.
Criteria 97acr Cohort, 82acr Cohort, OR 95% CI
n = 58 (%) n = 81 (%)
Malar rash 35 (60) 43 (53) 1.35 0.7–2.7
Discoid rash 18 (31) 48 (59) 0.31 0.2–0.6
Photosensitivity 30 (52) 53 (65) 0.57 0.3–1.1
Oral ulcers 12 (21) 25 (31) 0.58 0.3–1.3
Arthritis 31 (54) 67 (83) 0.24 0.1–0.5
Serositis 11 (19) 21 (26) 0.67 0.3–1.5
Renal disorder 7 (12) 27 (33) 0.28 0.1–0.7
Proteinuria 5 (9) 24 (31) 0.22 0.1–0.6
Casts 6 (10) 16 (20) 0.47 0.2–1.3
Neurological disorder 1 (2) 5 (5) 0.27 0.0–2.4
Hematological disorder 27 (47) 62 (77) 0.27 0.1–0.6
Leukopenia 16 (28) 42 (52) 0.35 0.2–0.7
Lymphopenia 15 (26) 47 (58) 0.25 0.1–0.5
Immunological disorder 43 (74) 57 (70) 1.21 0.6–2.8
LE cells 0 (0) 27 (33) — —
Anti-DNA antibodies 39 (67) 36 (44) 2.57 1.3–5.2
Anti-Sm antibodies 6 (10) 8 (10) 1.05 0.4–3.2
False-positive syphilis test 5 (9) 7 (9) 1.00 0.3–3.3
aPL 15 (26) 1 (1) 27.9 3.6–218
Antinuclear antibodies 53 (95) 78 (96) 0.41 0.1–1.8
Azathioprine 8 (14) 2 (3) 6.32 1.3–31.0
Methylprednisolone 6 (10) 1 (1) 9.23 1.1–78.9
Low-dose aspirin 12 (21) 0 (0) 20.9 2.6–165.7
For abbreviations see Table 1.
Table 3. Sex and age-adjusted standardized mortality ratio (SMR) for the various SLE cohorts and controls (C).
97acr Cohort, 1996–2006 82acr Cohort, 1978–1995 Whole Period, 1978–2006
SLE, Control, SMR 95% CI SLE, Control, SMR 95% CI SLE, Control, SMR 95% CI
n = 58 n = 290 n = 81 n = 405 n = 139 n = 695
No. Deaths No. Deaths No. Deaths
Children 0 0 NC — 0 0 NC — 0 0 NC —
Adults 5 5 3.00 1.6–5.8 25 55 1.88 1.3–2.7 30 60 2.00 1.4–2.8
Men 0 2 NC — 5 13 1.67 0.7–4.1 5 15 1.50 0.6–3.5
Women 5 3 3.75 2.1–6.8 20 42 1.94 1.3–2.9 25 45 2.14 1.5–3.1
Age at death, yrs
16–29 1 0 NC — 1 1 3.17 0.6–17.9 2 1 4.06 1.6–10.5
30–49 1 1 3.00 0.7–12.5 4 4 2.72 1.3–5.9 5 5 2.87 1.5–5.6
50–69 2 2 3.04 1.0–9.2 8 5 3.32 1.9–5.7 10 7 3.28 2.0–5.3
70+ 1 1 NC — 7 32 1.44 0.6–3.2 8 32 1.54 0.7–3.3
NC: not calculated. Children < 16 years.
DISCUSSION
In an effort to determine the validity of the 1997 update of
the ACR classification criteria for SLE, a longterm popula-
tion-based study of SLE was performed. The use of the
ACR97 criteria did not lead to changes in SLE incidence or
demographics, as all patients fulfilled the ACR82 criteria as
well. However, the clinical disease pattern did change over
time, with a significant reduction in the frequency of renal
disease and increased use of assays for lower avidity ds-
DNA and aPL antibody as classification criteria. Concurrent
increased use of early treatment with pulse methylpred-
nisolone, azathioprine, and low-dose aspirin and more
intense serological surveillance may have further con-
tributed to this “prevention” of renal disease with subse-
quent improvements in overall 5- and 10-year survival rates
for the whole cohort.
The negligible increase in SLE incidence during the last
decade is in accord with earlier observations from southern
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Figure 2. Survival among SLE patients in cohort 97acr (diagnosed by ACR97), cohort 82acr (diag-
nosed by ACR82), and control population. For cohort 97acr and controls p = 0.004 and for cohort
82acr and controls p < 0.001, by log-rank test.
Table 4. Predictors for mortality in SLE within 10 years after diagnosis, by univariate analysis (hazard ratio, both cohorts) and multivariate analysis (adjust-
ed HR, cohort 82acr only). Clinical criteria reflect findings at scientific diagnosis, drug treatment during the first 4 months after diagnosis, SLICC/ACR DI
> 0 one year after diagnosis, hypocomplementemia during first year of disease; and ever-positive test for aPL antibodies.
97acr Cohort 82acr Cohort Adjusted
Criteria Died, Alive, HR 95% CI Died, Alive, HR 95% CI HR 95% CI
n = 5 (%) n = 57 (%) n = 17 (%) n = 70 (%)
Age ≥ 50 yrs 2 (40) 10 (18) 2.2 0.4–13.4 13 (77) 10 (14) 11.5 3.7–35 12.2 3.3–46
Malar rash 2 (40) 35 (61) 0.4 0.1–2.6 6 (35) 43 (61) 0.4 0.1–0.9 0.8 0.2–2.4
Photosensitivity 2 (40) 30 (53) 0.5 0.1–3.2 8 (47) 48 (69) 0.4 0.2–1.1
Oral ulcers 0 21 (21) 0.04 0.0–651 2 (12) 26 (37) 0.2 0.1–1.0
Renal disorder 3 (60) 5 (9) 10.9 1.8–66 7 (42) 24 (34) 1.3 0.5–3.5
NSAID 3 (60) 23 (40) 1.8 0.3–10.7 5 (29) 40 (57) 0.4 0.1–1.0
Methylprednisolone 2 (40) 4 (7) 1.5 1.1–2.0 0 3 (4) 0.6 0.1–3.6
Cyclophosphamide 2 (40) 4 (7) 5.2 0.9–31 1 (6) 11 (16) 0.3 0.0–2.5
Low-dose aspirin 4 (80) 8 (14) 1.3 1.1–1.5 0 0
Antihypertensives 3 (60) 1 (2) 1.3 1.1–1.4 0 2 (3)
SLICC/ACR DI > 0 2 (40) 17 (30) 1.4 0.2–8.1 5 (29) 7 (10) 2.8 1.0–8.0 1.7 0.6–5.0
Low C3 3 (60) 11 (19) 5.4 0.9–32 6 (35) 31 (44) 0.7 0.3–1.9
Low C4 4 (80) 18 (32) 7.2 0.8–65 5 (29) 23 (33) 0.9 0.3–2.5
aPL 4 (80) 21 (37) 7.0 0.8–63 4 (24) 24 (34) 0.6 0.2–1.7
NSAID: nonsteroidal antiinflammatory drugs; SLICC/ACR DI: Systemic Lupus International Collaborating Clinics/ACR Damage Index; aPL: antiphospho-
lipid antibodies.
Sweden10. The average AIR (3.0 per 100,000 adults)
remains within the range of reported Scandinavian inci-
dence rates (1.5–4.8 per 100,000)3,5,6,10,23. Studies from
other regions give conflicting data. In the French West
Indies no changes in SLE incidence have occurred24, while
the Mayo Clinic in Rochester, MN, USA, describes a
tripling of SLE incidence in the period 1950-929. The
Rochester population has a strong Nordic background and
the overall incidence rate for the study was 3.0/100,0009,
similar to our data, so the increase observed in Rochester
may be a catchup effect. The trend towards increasing AIR
in women for the 30–49 age group (8.3) is in line with other
studies5,6,25, however, aside from the high AIR (14.1) seen
in women 65–74 years old in southern Sweden10. SLE
prevalence in Northern Norway was highest in post-
menopausal women (1.3 per 1,000), making SLE a disease
currently seen in 1 per 770 women in this age group. The
increasing overall prevalence (64.1 per 100,000 as of
January 1, 2007) is due to a stable disease incidence and
improved survival.
While not a primary aim of our study, we observed a sta-
ble incidence and no case fatalities in children with SLE in
northern Norway. The mean AIR was 0.9 per 100,000 for
children, somewhat higher compared with other studies on
Scandinavian cohorts23,26.
Despite few changes in epidemiological characteristics,
remarkable changes in the clinical presentation of SLE over
time occurred. The average number of classification criteria
at diagnosis decreased significantly, even though the time
from the first symptom attributable to SLE was 1 year in
both cohorts. Increased reliance on sensitive, although not
necessarily specific, autoantibody assays for anti-dsDNA
and aPL seems to have become an essential part of the diag-
nostic investigation and classification process. The fact that
overall disease activity at diagnosis was similar is not in
contradiction with this, as the SLEDAI incorporates several
recognized disease manifestations not covered by the classi-
fication criteria (e.g., alopecia, vasculitis, cerebrovascular
accidents, fever, and hypocomplementemia). These data
thus imply that, currently, physicians with the use of
sensitive assays recognize SLE at an earlier stage before
severe and/or multi-organ presentation develops and also
include serological surveillance more often in patient
management27.
The decrease in the number of patients with lupus nephri-
tis in the 97acr cohort in our study is especially intriguing.
Most studies link lupus nephritis to the presence of nephri-
togenic high avidity anti-dsDNAAb as detected by C. lucil-
iae immunofluorescence or the Farr radioactivity assay28-30.
Anti-dsDNA Ab are, however, often present long before
SLE is clinically apparent and they gradually obtain their
nephritogenic potential through repeated antigenic stimula-
tion28,31,32. Several short-term prospective studies have
shown that intensive anti-dsDNA Ab surveillance can help
prevent disease flares such as lupus nephritis33,34. In our
study the 97acr cohort was surveyed more frequently for
early serological disease markers, had increased early treat-
ment with pulse steroids and azathioprine, and generally had
milder lupus. Altogether this may lend support to the accu-
mulated theory on lupus development. While our observa-
tional data only provide circumstantial evidence, they at
least support the idea that severe lupus could be prevented
by intervening in the mechanism behind the antibody matu-
ration response and thereby reducing the risk of renal dis-
ease and attaining the goal of milder lupus.
It is, however, important to note that established renal
disease remained a strong risk factor for reduced short-term
survival (HR 10.9)35-37. Therefore, lupus nephritis remains a
potentially severe, although now less frequent, complication
of SLE in Caucasian patients, and the use of serological sur-
veillance in the prevention of lupus nephritis deserves fur-
ther study.
A similar case can be made for increased surveillance for
aPL antibodies. aPL screening was reinforced by theACR97
criteria, and aPL Ab are detectable in the serum of patients
with SLE many years before diagnosis and prior even to
anti-dsDNAAb32,38. While the pathogenic characteristics of
aPL are less well defined than for anti-dsDNAAb, increased
serological surveillance likely contributed to earlier identifi-
cation of cases in the 97acr cohort, and clearly contributed
to patient management measures as illustrated by the pre-
ventive treatment with low-dose aspirin in 21% of newly
diagnosed patients39.
Patients with SLE in northern Norway remain at risk of
premature death, as indicated by the overall SMR of 2.00 for
the whole study period. During the 1970s and 1990s, SMR
for lupus cohorts ranged between 2.7 and 4.9 around the
world40-42. Some studies from the last decade report
decreasing SMR, with a study from Greece reporting a SMR
of only 1.536,43. In our study, SMR was higher in cohort
97acr (3.00) than in cohort 82acr (1.88). Mortality in SLE
has been described as having a bimodal pattern, with an
early mortality peak mainly due to active disease and a later
peak associated to cardiovascular complications44,45. Given
the disease duration of only 19 months at death in the 97acr
cohort, this increased SMR can likely represent the first
peak in the mortality curve. Alternatively, the increased
SMR may reflect a larger reduction in mortality in the con-
trol group than in the SLE cohort due to improved general
healthcare delivery and living standards. For the whole peri-
od, SMR was highest in women under 30 years of age and
lowest in the elderly, similar to data from various other
cohorts36,40,41.
Both 5- and 10-year survival rates were improved for the
97acr cohort compared with 82acr cohort, in line with other
single-center studies10,46. This development naturally
reflects the combined effects of earlier case recognition with
subsequent inclusion of patients with milder form of dis-
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ease, advances in therapeutic modalities, and more judicious
use of existing therapies such as hydroxychloroquine47.
Cardiovascular disease is an increasingly important contrib-
utor to SLE mortality, and together with infections is the
most frequent cause of death19,41,48; and while low numbers
did not allow detailed analyses, causes of death in cohort
97acr were also mainly cardiovascular (40%) and infectious
(40%), with 1 patient in a fatal accident (20%).
Of necessity, our study is observational and we are aware
of the biases incurred by such study design and the relative-
ly low number of patients. While the use of an earlier-incep-
tion cohort, the single-center setting, and the long followup
time provided some measure of control, selection bias may
nonetheless have influenced our conclusions, which will
need further confirmation. The differences in observation
times precluded any firm conclusions on mortality differ-
ences between the 2 cohorts, while low numbers did not
allow us to perform statistically meaningful analyses of spe-
cific causes of death.
The ACR97 criteria set was found to have excellent con-
struct validity compared to the ACR82 criteria. While the
incidence of SLE in northern Norway remained constant
between 1978 and 2006, an increase in the use of serological
classification criteria coincided with a notable reduction in
prevalence of lupus nephritis. The increased use of a sensitive
ELISA for anti-dsDNA and aPL antibodies may thus have
allowed earlier identification of patients at risk for severe dis-
ease. Together with a more aggressive therapeutic approach,
this seems to have contributed to milder lupus in a number of
patients, with subsequent improvements in survival.
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